Literature DB >> 17631093

Comparison of speed of onset of platelet inhibition after loading doses of clopidogrel versus prasugrel in healthy volunteers and correlation with responder status.

Govinda J Weerakkody1, Joseph A Jakubowski, John T Brandt, Nagy A Farid, Christopher D Payne, Jianyu Zhu, Margaret R Warner, Hideo Naganuma, Kenneth J Winters.   

Abstract

Failure to achieve an adequate level of platelet inhibition during percutaneous coronary intervention is associated with an increased risk for periprocedural myocardial injury. This study was conducted to compare the initial rate of platelet inhibition after a loading dose (LD) of prasugrel or clopidogrel and determine the association between the initial rate of inhibition and pharmacodynamic responder status. Data were pooled from 3 studies in which healthy subjects received LDs of prasugrel (60 mg; n = 76) or clopidogrel (300 mg; n = 87). Maximum platelet aggregation (MPA; 20 mumol/L adenosine diphosphate) was measured by turbidimetric aggregometry (0.25 to 24 hours after dosing). A mechanistic model was used to estimate the initial rate of decrease in MPA per hour (fast onset: MPA decrease >20%/hour). Subjects were defined as pharmacodynamic poor responders if the absolute decrease in MPA from baseline was <15% at either 4 to 5 or 24 hours after dosing. The median initial rate of decrease in MPA was greater after prasugrel (203%/hour) than with clopidogrel (23%/hour) (p <0.001). Overall, 76 subjects (100%) receiving prasugrel had fast onset of platelet inhibition compared with 47 subjects (54%) receiving clopidogrel. The initial rate of decrease in MPA was highly correlated with responder status (p <0.001). After prasugrel, subjects had a lower median MPA compared with clopidogrel (p <0.001; from >0.25 to 24 hours after dosing), and intersubject variability in MPA response was less after prasugrel compared with clopidogrel (p <0.001; from >1 to 24 hours after dosing). In conclusion, platelet inhibition after a 60-mg LD of prasugrel was more rapid in onset, less variable, and greater in magnitude than with a 300-mg LD of clopidogrel. After a thienopyridine LD, the initial rate of platelet inhibition was predictive of pharmacodynamic responder status.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17631093     DOI: 10.1016/j.amjcard.2007.02.103

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  7 in total

Review 1.  P2Y12 antagonists in non-ST-segment elevation acute coronary syndromes: latest evidence and optimal use.

Authors:  Nicholas B Norgard; James J DiNicolantonio
Journal:  Ther Adv Chronic Dis       Date:  2015-07       Impact factor: 5.091

2.  Clinical importance of aspirin and clopidogrel resistance.

Authors:  Gergely Feher; Andrea Feher; Gabriella Pusch; Katalin Koltai; Antal Tibold; Beata Gasztonyi; Elod Papp; Laszlo Szapary; Gabor Kesmarky; Kalman Toth
Journal:  World J Cardiol       Date:  2010-07-26

Review 3.  Comparing newer oral anti-platelets prasugrel and ticagrelor in reduction of ischemic events-evidence from a network meta-analysis.

Authors:  Saurav Chatterjee; Abhimanyu Ghose; Abhishek Sharma; Gunjan Guha; Debabrata Mukherjee; Robert Frankel
Journal:  J Thromb Thrombolysis       Date:  2013-10       Impact factor: 2.300

4.  Hemorrhagic complications after prasugrel (Effient) therapy for vascular neurointerventional procedures.

Authors:  S Hassan Akbari; Matthew R Reynolds; Yasha Kadkhodayan; Dewitte T Cross; Christopher J Moran
Journal:  J Neurointerv Surg       Date:  2012-05-03       Impact factor: 5.836

5.  Does tirofiban prevent platelet loss in patients after cardiogenic shock during continuous renal replacement therapy?

Authors:  Christian Storm; Achim Jörres
Journal:  Crit Care       Date:  2008-11-24       Impact factor: 9.097

Review 6.  Comparison of prasugrel and clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention.

Authors:  Nicholas B Norgard; Mazen Abu-Fadel
Journal:  Vasc Health Risk Manag       Date:  2009-11-02

7.  The Pharmacokinetics and Pharmacodynamics of Prasugrel and Clopidogrel in Healthy Japanese Volunteers.

Authors:  Kazuo Umemura; Takayuki Iwaki
Journal:  Clin Pharmacol Drug Dev       Date:  2016-04-25
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.